NASDAQ:SVA - Sinovac Biotech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.58 -0.07 (-0.92 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$7.65
Today's Range$7.51 - $7.60
52-Week Range$4.67 - $8.75
Volume4,700 shs
Average Volume56,410 shs
Market Capitalization$432.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.14

About Sinovac Biotech (NASDAQ:SVA)

Sinovac Biotech logoSinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against enterovirus71 (EV710), hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; and split viron pandemic influenza vaccine. The company also completed phase III clinical trials for EV71, varicella, and pneumococcal polysaccharide vaccines. In addition, it has completed pre-clinical studies for sabin inactivated polio; and focuses on commencing clinical trials for pneumococcal conjugate, Quadrivalent influenza, and rubella vaccines. The company has a collaboration agreement with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SVA
CUSIPN/A
Phone86-10-8289-0088

Debt

Debt-to-Equity Ratio0.08
Current Ratio2.20
Quick Ratio1.99

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.35 million
Price / Sales2.48
Cash Flow$0.5104 per share
Price / Cash14.85
Book Value$3.11 per share
Price / Book2.44

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees724
Outstanding Shares57,020,000

Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

How were Sinovac Biotech's earnings last quarter?

Sinovac Biotech (NASDAQ:SVA) posted its quarterly earnings data on Tuesday, August, 23rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter. The biopharmaceutical company had revenue of $1.38 billion for the quarter, compared to analysts' expectations of $18.49 billion. During the same period in the previous year, the business earned $0.02 EPS. View Sinovac Biotech's Earnings History.

Who are some of Sinovac Biotech's key competitors?

Who are Sinovac Biotech's key executives?

Sinovac Biotech's management team includes the folowing people:
  • Mr. Ming Xia, VP of Sales & Marketing (Age 44)
  • Dr. Weidong Yin, Chairman, Pres, CEO, MD & Sec. (Age 53)
  • Ms. Nan Wang, CFO & VP of Bus. Devel. (Age 52)
  • Mr. Gao Qiang, VP of R&D (Age 41)
  • Ms. Li Jing, VP of Quality & Production (Age 43)

Has Sinovac Biotech been receiving favorable news coverage?

Media coverage about SVA stock has been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sinovac Biotech earned a news sentiment score of 0.11 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.69 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Sinovac Biotech's major shareholders?

Sinovac Biotech's stock is owned by many different of institutional and retail investors. Top institutional investors include 1GLOBE CAPITAL LLC Total Shares: 9,353,092 (16.40%), 1GLOBE CAPITAL LLC Total Shares: 9,353,092 (16.40%) and California Public Employees Retirement System (0.16%). Company insiders that own Sinovac Biotech stock include James Todd Parsons and Scott Langille. View Institutional Ownership Trends for Sinovac Biotech.

Which major investors are buying Sinovac Biotech stock?

SVA stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. View Insider Buying and Selling for Sinovac Biotech.

How do I buy shares of Sinovac Biotech?

Shares of SVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sinovac Biotech's stock price today?

One share of SVA stock can currently be purchased for approximately $7.58.

How big of a company is Sinovac Biotech?

Sinovac Biotech has a market capitalization of $432.21 million and generates $174.35 million in revenue each year. Sinovac Biotech employs 724 workers across the globe.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is 39 SHANGDI XI ROAD HAIDIAN DISTRICT, BEIJING F4, 100085. The biopharmaceutical company can be reached via phone at 86-10-8289-0088 or via email at [email protected]


MarketBeat Community Rating for Sinovac Biotech (SVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe SVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sinovac Biotech (NASDAQ:SVA) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/23/2016 forward)

Earnings

Sinovac Biotech (NASDAQ:SVA) Earnings History and Estimates Chart

Earnings by Quarter for Sinovac Biotech (NASDAQ:SVA)

Sinovac Biotech (NASDAQ SVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/22/2017Q4 2016$0.08$31.37 millionViewN/AView Earnings Details
11/28/2016Q316$0.05$0.06$16.76 million$28.74 millionViewN/AView Earnings Details
8/23/2016Q2($0.15)$18.49 billion$1.38 billionViewListenView Earnings Details
5/26/2016Q116($0.01)$10.95 millionViewN/AView Earnings Details
4/5/2016Q415$0.01$22.95 millionViewN/AView Earnings Details
11/11/2015Q315($0.02)($0.03)$27.10 million$16.80 millionViewListenView Earnings Details
8/12/2015Q215($0.01)$0.04$15.70 million$18.50 millionViewListenView Earnings Details
5/15/2015Q115$0.02($0.04)$12.70 million$9.27 millionViewN/AView Earnings Details
4/20/2015Q414$0.01$0.02$14.10 million$22.90 millionViewN/AView Earnings Details
8/14/2014Q214$0.01($0.04)$17.20 million$12.10 millionViewN/AView Earnings Details
3/19/2014Q4 13($0.01)$0.10$18.75 million$22.90 millionViewN/AView Earnings Details
11/12/2013Q3$0.04$22.08 millionViewListenView Earnings Details
8/13/2013Q2 2013$0.02$17.45 millionViewN/AView Earnings Details
5/28/2013Q1 2013($0.04)$10.05 millionViewN/AView Earnings Details
4/18/2013Q4 2012($0.08)ViewN/AView Earnings Details
11/15/2012Q312($0.03)($0.06)$12.35 million$14.30 millionViewN/AView Earnings Details
8/15/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.13)($0.10)ViewN/AView Earnings Details
3/29/2012Q4 2011$0.05ViewN/AView Earnings Details
11/14/2011Q3 2011$0.02($0.04)ViewN/AView Earnings Details
8/12/2011Q2 2011($0.01)$0.02ViewN/AView Earnings Details
5/13/2011Q1 2011($0.05)ViewN/AView Earnings Details
3/31/2011Q4 2010$0.02($0.17)ViewN/AView Earnings Details
11/15/2010Q3 2010$0.05($0.01)ViewN/AView Earnings Details
8/16/2010Q2 2010$0.01$0.02ViewN/AView Earnings Details
5/13/2010Q1 2010$0.02($0.01)ViewN/AView Earnings Details
4/6/2010Q4 2009$0.21ViewN/AView Earnings Details
11/15/2009Q3 2009$0.07$0.12ViewN/AView Earnings Details
8/19/2009Q2 2009$0.14ViewN/AView Earnings Details
4/9/2009Q4 2008$0.04$0.06ViewN/AView Earnings Details
11/18/2008Q3 2008$0.03$0.02ViewN/AView Earnings Details
8/13/2008Q2 2008$0.08$0.08ViewN/AView Earnings Details
5/16/2008Q1 2008$0.04ViewN/AView Earnings Details
3/31/2008Q4 2007$0.05$0.05ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sinovac Biotech (NASDAQ:SVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sinovac Biotech (NASDAQ SVA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 11.97%
Insider Trading History for Sinovac Biotech (NASDAQ:SVA)
Institutional Ownership by Quarter for Sinovac Biotech (NASDAQ:SVA)

Sinovac Biotech (NASDAQ SVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2017Scott LangilleInsiderBuy100,000$0.27$27,000.00
4/19/2017Scott LangilleInsiderBuy50,000$0.27$13,500.00
4/18/2017Scott LangilleInsiderBuy25,000$0.26$6,500.00
4/17/2017James Todd ParsonsDirectorSell272$0.25$68.00
4/17/2017Scott LangilleInsiderBuy24,500$0.26$6,370.00
4/13/2017James Todd ParsonsDirectorSell166,500$0.25$41,625.00
4/11/2017James Todd ParsonsDirectorSell33,500$0.25$8,375.00
12/30/2015Jeffrey BachaDirectorSell10,000$0.2950$2,950.00
12/29/2015Jeffrey BachaDirectorSell21,500$0.2950$6,342.50
(Data available from 1/1/2013 forward)

Headlines

Sinovac Biotech (NASDAQ SVA) News Headlines

Source:
DateHeadline
Sinovac reports strong performance in H2 2017; shares up 4%Sinovac reports strong performance in H2 2017; shares up 4%
seekingalpha.com - May 11 at 4:28 PM
Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial ResultsSinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results
finance.yahoo.com - May 11 at 10:26 AM
Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac BeijingSinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
finance.yahoo.com - May 8 at 4:26 PM
Sinovac Biotech Says Forced To Temporarily Suspend Flu Vaccine ProductionSinovac Biotech Says Forced To Temporarily Suspend Flu Vaccine Production
www.nasdaq.com - May 1 at 9:30 AM
Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac BeijingSinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing
finance.yahoo.com - May 1 at 9:30 AM
Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site InspectionSinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection
finance.yahoo.com - April 30 at 9:41 AM
Sinovac Temporarily Blocks Access to Its WebsitesSinovac Temporarily Blocks Access to Its Websites
finance.yahoo.com - April 30 at 9:41 AM
Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac BeijingSinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing
finance.yahoo.com - April 27 at 10:02 AM
Sinovac Resumes Production and Operation at Sinovac Beijings Quality Assurance DepartmentSinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department
finance.yahoo.com - April 24 at 9:28 AM
Sinovac Biotech (SVA) Reports Prelim. Results of Phase 3 Clinical Study on Sabin Inactivated Polio Vaccine (sIPV)Sinovac Biotech (SVA) Reports Prelim. Results of Phase 3 Clinical Study on Sabin Inactivated Polio Vaccine (sIPV)
www.streetinsider.com - April 21 at 9:20 AM
Sinovac Bio in (literal) tussle with activist investorSinovac Bio in (literal) tussle with activist investor
seekingalpha.com - April 19 at 9:29 AM
Sinovac Announces Preliminary Results of Phase III Trial on sIPVSinovac Announces Preliminary Results of Phase III Trial on sIPV
finance.yahoo.com - April 19 at 9:29 AM
Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.
finance.yahoo.com - April 18 at 4:41 PM
Sinovac Biotech (SVA) Stock Rating Lowered by BidaskClubSinovac Biotech (SVA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 13 at 11:10 PM
Sinovac Biotech (SVA) Rating Lowered to Buy at BidaskClubSinovac Biotech (SVA) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 13 at 9:39 AM
Sinovac Biotech (SVA) Lifted to "Buy" at BidaskClubSinovac Biotech (SVA) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 10 at 1:42 PM
BidaskClub Lowers Sinovac Biotech (SVA) to HoldBidaskClub Lowers Sinovac Biotech (SVA) to Hold
www.americanbankingnews.com - April 6 at 6:29 PM
Why Sinovac Biotech Ltd’s (NASDAQ:SVA) ROE Of 18.01% Does Not Tell The Whole StoryWhy Sinovac Biotech Ltd’s (NASDAQ:SVA) ROE Of 18.01% Does Not Tell The Whole Story
finance.yahoo.com - March 31 at 9:25 AM
Sinovac Biotech (SVA) Rating Increased to Buy at BidaskClubSinovac Biotech (SVA) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 30 at 10:02 PM
Sinovac Biotech (SVA) Upgraded at BidaskClubSinovac Biotech (SVA) Upgraded at BidaskClub
www.americanbankingnews.com - March 30 at 11:06 AM
Sinovac Biotech (SVA) Rating Lowered to Hold at BidaskClubSinovac Biotech (SVA) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 29 at 3:01 PM
Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private TransactionSinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction
finance.yahoo.com - March 27 at 10:00 AM
BRIEF-Sinovac Biotech Says All Five Of Cos Incumbent Directors Were Re-Elected At AGM By Majority Of Votes Validly CastBRIEF-Sinovac Biotech Says All Five Of Co's Incumbent Directors Were Re-Elected At AGM By Majority Of Votes Validly Cast
www.reuters.com - March 16 at 9:47 AM
Sinovac Biotech (SVA) Comments on False Statements by Unauthorized Third PartiesSinovac Biotech (SVA) Comments on False Statements by Unauthorized Third Parties
www.streetinsider.com - March 16 at 9:47 AM
Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third PartiesSinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties
finance.yahoo.com - March 15 at 9:25 AM
What Does Sinovac Biotech Ltd’s (NASDAQ:SVA) Ownership Structure Look Like?What Does Sinovac Biotech Ltd’s (NASDAQ:SVA) Ownership Structure Look Like?
finance.yahoo.com - March 14 at 5:39 PM
Sinovac Newly-Elected Board of Directors Response to the Announcement of the Purported Re-Election of All Directors at the February 6, 2018 Annual General MeetingSinovac Newly-Elected Board of Directors' Response to the Announcement of the Purported Re-Election of All Directors at the February 6, 2018 Annual General Meeting
finance.yahoo.com - March 14 at 10:31 AM
Baxalta (BXLT) vs. Sinovac Biotech (SVA) Financial ComparisonBaxalta (BXLT) vs. Sinovac Biotech (SVA) Financial Comparison
www.americanbankingnews.com - March 10 at 5:07 PM
Sinovac Amends Shareholder Rights PlanSinovac Amends Shareholder Rights Plan
finance.yahoo.com - March 6 at 4:47 PM
Sinovac Announces Re-Election of All Directors at Annual General MeetingSinovac Announces Re-Election of All Directors at Annual General Meeting
finance.yahoo.com - March 5 at 4:58 PM
Sinovac Biotech (SVA) & Biogen (BIIB) Financial ComparisonSinovac Biotech (SVA) & Biogen (BIIB) Financial Comparison
www.americanbankingnews.com - February 20 at 5:32 PM
Sinovac Holds 2017 Annual General Meeting of ShareholdersSinovac Holds 2017 Annual General Meeting of Shareholders
finance.yahoo.com - February 7 at 9:12 AM
Sinovac Provides Update on Going Private TransactionSinovac Provides Update on Going Private Transaction
finance.yahoo.com - February 7 at 9:12 AM
Analyzing Sinovac Biotech (SVA) and Catalyst Biosciences (CBIO)Analyzing Sinovac Biotech (SVA) and Catalyst Biosciences (CBIO)
www.americanbankingnews.com - February 3 at 1:28 PM
Critical Comparison: Sinovac Biotech (SVA) and Synlogic (SYBX)Critical Comparison: Sinovac Biotech (SVA) and Synlogic (SYBX)
www.americanbankingnews.com - February 1 at 1:12 AM
An open letter from Sinobioway Consortium to all shareholders of Sinovac Biotech Ltd. ("SVA")An open letter from Sinobioway Consortium to all shareholders of Sinovac Biotech Ltd. ("SVA")
www.bizjournals.com - January 31 at 4:29 PM
Analyzing Catalyst Biosciences (CBIO) & Sinovac Biotech (SVA)Analyzing Catalyst Biosciences (CBIO) & Sinovac Biotech (SVA)
www.americanbankingnews.com - January 12 at 7:48 AM
Reviewing Myovant Sciences (MYOV) and Sinovac Biotech (SVA)Reviewing Myovant Sciences (MYOV) and Sinovac Biotech (SVA)
www.americanbankingnews.com - January 6 at 11:36 PM
What You Must Know About Sinovac Biotech Ltd’s (NASDAQ:SVA) RisksWhat You Must Know About Sinovac Biotech Ltd’s (NASDAQ:SVA) Risks
finance.yahoo.com - January 5 at 3:23 PM
Sinovac Schedules 2017 Annual Meeting of ShareholdersSinovac Schedules 2017 Annual Meeting of Shareholders
finance.yahoo.com - December 29 at 8:52 AM
Should You Be Tempted To Buy Sinovac Biotech Ltd (NASDAQ:SVA) Because Of Its PE Ratio?Should You Be Tempted To Buy Sinovac Biotech Ltd (NASDAQ:SVA) Because Of Its PE Ratio?
finance.yahoo.com - December 28 at 1:49 PM
Sinovac Biotech (SVA) Cut to Hold at BidaskClubSinovac Biotech (SVA) Cut to Hold at BidaskClub
www.americanbankingnews.com - December 27 at 9:53 AM
Anika Therapeutics (ANIK) vs. Sinovac Biotech (SVA) Critical ReviewAnika Therapeutics (ANIK) vs. Sinovac Biotech (SVA) Critical Review
www.americanbankingnews.com - December 24 at 3:30 PM
Sinovac Biotech (SVA) Announces Positive Decision on its Hepatitis A Vaccine from World Health OrganizationSinovac Biotech (SVA) Announces Positive Decision on its Hepatitis A Vaccine from World Health Organization
www.streetinsider.com - December 22 at 3:39 PM
Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health OrganizationSinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization
finance.yahoo.com - December 22 at 3:39 PM
Sinovac Biotech (SVA) Downgraded by BidaskClub to BuySinovac Biotech (SVA) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - December 7 at 10:32 PM
Critical Analysis: Chiasma (CHMA) and Sinovac Biotech (SVA)Critical Analysis: Chiasma (CHMA) and Sinovac Biotech (SVA)
www.americanbankingnews.com - December 6 at 1:28 AM
Sinovac Biotech Now In Compliance With All Listing Standards - Quick FactsSinovac Biotech Now In Compliance With All Listing Standards - Quick Facts
www.rttnews.com - December 1 at 7:51 AM
Sinovac Biotech Cures Nasdaq Filing DeficiencySinovac Biotech Cures Nasdaq Filing Deficiency
finance.yahoo.com - December 1 at 7:51 AM
Sinovac Reports Unaudited First Half of 2017 Financial ResultsSinovac Reports Unaudited First Half of 2017 Financial Results
finance.yahoo.com - December 1 at 7:51 AM

SEC Filings

Sinovac Biotech (NASDAQ:SVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sinovac Biotech (NASDAQ:SVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sinovac Biotech (NASDAQ SVA) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.